Malnutrition is the second most common diagnosis in cancer patients, affecting 40–80% depending on tumor type, stage, and treatment modality. Cancer-associated malnutrition reduces chemotherapy tolerance, increases surgical complication rates, decreases response to treatment, reduces quality of life, and is an independent predictor of cancer-specific and overall survival. Yet routine nutritional assessment and intervention remain inconsistent in oncology practice. Evidence-based oncology nutrition — including proactive screening, early dietitian involvement, and appropriate clinical nutrition products — represents a high-yield, underutilized intervention in comprehensive cancer care. Our clinical nutrition catalog includes oncology-appropriate enteral formulas, oral supplements, and parenteral nutrition components.
Cancer Cachexia: Beyond Malnutrition
Cancer cachexia — present in 50–80% of advanced cancer patients — is a distinct syndrome from simple malnutrition, driven by tumor-induced metabolic abnormalities: elevated inflammatory cytokines (IL-6, TNF-α, IL-1β) that drive muscle protein catabolism, metabolic hyperactivity, and anorexia independently of nutritional intake. Cachexia is defined as >5% involuntary weight loss in 6 months (or BMI <20 with >2% weight loss, or appendicular skeletal muscle index below sex-specific thresholds) and is refractory to standard nutritional support alone in its advanced stage. Three cachexia phases: pre-cachexia (early, reversible), cachexia (established, partially reversible), and refractory cachexia (end-stage disease, irreversible). Early intervention in the pre-cachexia phase — before substantial weight loss and muscle wasting — produces better outcomes than late intervention. ESPEN oncology nutrition guidelines (2021) recommend nutritional screening at every oncology visit and dietitian referral for all patients with active weight loss or eating-related symptoms.
Nutritional Intervention Evidence
Oral nutritional supplements: high-protein, calorie-dense supplements (1.5–2.0 kcal/mL, 15–20g protein/200mL serving) reduce weight loss and improve QoL in head and neck cancer patients with treatment-related dysphagia — the best-studied ONS application. Eicosapentaenoic acid (EPA, omega-3): EPA 2g/day demonstrated weight stabilization and lean mass preservation in cachexia RCTs — now incorporated in specialized cachexia formulas (Forticare, Resource Support). Fortasyn Connect, ProSure, and similar oncology nutrition products are available in our nutrition catalog. For patients unable to maintain adequate oral intake: nasogastric or jejunal feeding tubes should be placed early in patients undergoing head and neck radiation with predictable severe mucositis — prophylactic PEG placement reduces acute weight loss and treatment interruptions in this population. Our nutrition section includes enteral feeding tubes, feeding sets, and pump supplies for oncology nutrition programs.
